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Abstract 
Review on Renal cell carcinomas with MiT family 
translocations, with data on clinics, and the genes 
involved. 
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chromosome X; chromosome 1; chromosome 6; 
chromosome 17. 
Clinics and pathology 
Disease 
Xp11 translocation renal cell carcinomas (RCCs) 
harbor gene fusions involving TFE3 transcription 
factor. The t(6;11) RCCs harbor a specific MALAT1 
(Alpha)-TFEB gene fusion.  TFEB and TFE3 belong 
to the same MiT subfamily of transcription factors 
(MiT for microphthalmia-TFE). Because of 
similarities at the clinical, morphologic, 
immunohistochemical, and genetic levels, the Xp11 
translocation RCCs and t(6;11) RCCs are currently 
grouped together under the category of MiT family 
translocation renal cell carcinoma. 
Epidemiology 
Xp11 translocation RCC are the most common RCC 
in children, and comprises approximately 1% of 
adult RCC. There are only approximately 50 
reported cases of t(6;11) RCC, median age is 31 
years. Both RCC have been associated with prior 
exposure to cytotoxic chemotherapy. 
Clinics 
These form masses in the kidney. Xp11 translocation 
RCC are frequently calcified on imaging. 
Pathology 
Xp11 translocation RCC most commonly feature 
papillary architecture and epithelioid clear cells, 
with abundant psammoma bodies. Xp11 
translocation RCCs can also present with unusual 
morphology mimicking other types of RCCs. Xp11 
translocation RCCs can show solid or nested growth 
with clear to granular eosinophilic cytoplasm 
mimicking clear cell RCC, multilocular cystic RCC-
like features,  anaplastic/pleomorphic giant cells, 
tubular growth reminiscent of collecting duct 
carcinoma, well-developed fascicles of spindled 
neoplastic cells with bland nuclei in focal myxoid 
stroma mimicking mucinous tubular and spindle cell 
carcinoma, sarcomatoid change, oncocytic areas 
mimicking oncocytoma, oncocytic spindled areas 
resembling epithelioid angiomyolipoma, trabecular 
patterns mimicking carcinoid tumor, and 
colonization of renal pelvic urothelium mimicking 
urothelial carcinoma.  
The t(6;11) RCC typically demonstrates a distinctive 
biphasic morphology, comprising larger epithelioid 
cells and small cells clustered around basement 
membrane material.  The larger epithelioid cells may 
have clear to eosinophilic cytoplasm, and their 
nested architecture is similar to that of clear cell 
RCC.  The smaller cells clustered around basement 
membrane material resemble the Call-Exner bodies 
of adult granulosa cell tumor. 
These neoplasms typically do not show prominent 
cytologic atypia or mitotic activity. While these 
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lesions appear well delineated grossly, 
microscopically they characteristically entrap single 
native renal tubules at their periphery. Over time and 
with greater experience a broad range of 
morphologic appearances have been found in the 
t(6;11) RCC.   
Some of the illustrated morphologic appearances in 
genetically-confirmed cases include extensive 
hyalinization (both nodular mass-forming 
hyalinization and diffuse pericellular hyalinization), 
papillary architecture mimicking papillary RCC, 
clear cell morphology with an absence of smaller 
cells mimicking clear cell RCC, oncocytoma like 
morphology, oncocytic papillary morphology, cystic 
dilatation of entrapped renal tubules leading to a 
grossly cystic appearance, tubulocystic carcinoma-
like morphology, and higher grade nested 
architecture which raises the broad differential 
diagnosis of high grade unclassified RCC. 
Treatment 
Surgical excision. 
Cytogenetics 
Cytogenetics Morphological 
See Table 1. 
Result of the chromosomal 
anomaly 
Fusion Protein 
Description 
Xp11 translocation renal cell carcinomas (RCCs) 
demonstrate fusion of the TFE3 transcription factor 
gene with one of multiple reported genes including 
ASPSCR1 (ASPL), PRCC, NONO (p54nrb), SFPQ 
(PSF), and, lastly, CLTCin the t(X;17)(p11.2;q23) 
Table 1). The two most common Xp11 translocation 
RCCs are those bearing the t(X;1)(p11.2;q21) which 
fuses the PRCC and TFE3 genes and the 
t(X;17)(p11.2;q25)which fuses the ASPSCR1 and 
TFE3 genes. The ASPSCR1/TFE3 gene fusion is the 
same gene fusion found in alveolar soft part sarcoma 
(ASPS), a rare pediatric neoplasm of uncertain 
histogenesis.
 
 
Neoplasm Fusion 
Age Range 
(years) 
Translocation 
ASPS ASPSCR1/TFE3 1-71 der(17)(X;17)(p11.2q25) 
RCC ASPSCR1/TFE3 1-75 t(X;17)(p11.2;q25) 
RCC PRCC/TFE3 2-69 t(X;1)(p11.2;q21) 
RCC SFPQ/TFE3 3-68 t(X;1)(p11.2;p34) 
RCC NONO/TFE3 29-51 inv(X)(p11.2q12) 
RCC CLTC/TFE3 14 t(X;17)(p11.2;q23) 
RCC PARP14/TFE3 32 t(X;3)(p11.2;q23) 
RCC DVL2/TFE3 73 t(X;17)(p11;p13) 
RCC LUC7L3/TFE3   t(X;17)(p11;q21) 
RCC  RBM10/TFE3 32 inv(X)(p11.2p11.23) 
RCC  KHSRP/TFE3   t(X;19)(p11.2;p13) 
Xp11 PEComa 
SFPQ/TFE3, NONO/TFE3 
and others 
9-55 
t(X;1)(p11.2;p34), inv(X)(p11.2q12) 
and others 
Melanotic Xp11 Translocation 
Cancer 
SFPQ/TFE3 and likely others 11-55 t(X;1)(p11.2;q34) and likely others 
Subset of Epithelioid 
Hemangioendothelioma 
YAP1/TFE3 14-50 t(X;11)(p11.2;q13) 
RCC MALAT1(Alpha)-TFEB 3-68 t(6;11)(p21;q12) 
RCC CLTC/TFEB   t(6;17)(p21;q23) 
RCC KHDRBS2/TFEB   inv(6)(p21q11)  
RCC COL21/TFEB   inv(6)(p21p12) 
RCC TFEB/CADM2   t(3;6)(p12;p21) 
Table 1. TFE3 or TFEB Gene Fusions ASPS= Alveolar soft part  sarcoma, RCC= Renal cell carcinoma, PEComa= Perivascular 
epithelioid cell tumor 
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Other common translocations are the inv 
(X)(p11.2q12) which fuses the NONO (p54nrb) and 
TFE3 genes; the t(X;1)(p11.2;p34) which fuses the 
SFPQ (PSF) and TFE3 genes. Although native TFE3 
transcription factor protein is ubiquitously 
expressed, its normal levels are generally 
undetectable by immunohistochemistry. However, 
the TFE3 gene fusion partners in the Xp11 
translocation RCC contribute strong promoters 
leading to overexpression of the fusion protein and 
strong nuclear labeling for TFE3 by 
immunohistochemistry.  
The t(6;11)(p21;q12) translocation fuses the gene for 
transcription factor EB ( TFEB) with MALAT1 
(Alpha), an untranslated gene of unknown function, 
resulting in overexpression of native TFEB. Along 
these lines, the t(6;11) RCCs (also known as Alpha-
TFEB RCCs) demonstrate specific nuclear labeling 
for TFEB protein by immunohistochemistry, 
whereas TFEB protein is not detected by 
immunohistochemistry in other neoplasms and 
normal tissues. 
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